naion glp-1 news RA Weight Loss Drugs May Carry Untold Ocular Burden Popular Type 2 Diabetes Drug

Until recently they have had little support from the two dominant GLP-1 drug makers, Novo Nordisk and Eli Lilly who have not considered addition a high prioroty (Sheridan)

More than weight loss: GLP-1s reshape spending and self-control GLP-1 medications are doing more than supporting weight loss

Third, the TRIUMPH-4 population (obesity plus knee OA) is slightly different from the STEP-1 and SURMOUNT-1 populations (general obesity), so the definitive head-to-head comparison waits for TRIUMPH-1

Kraft M, Kraft K, Grtner S, Mayerle J, Simon P, Weber E, Schtte K, Stieler J, Koula-Jenik H, Holzhauer P, Grber U, Engel G, Mller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM